Projects

Lp(a)HORIZON: Lipoprotein(a) Lowering with Pelacarsen Did Not Reduce Cardiovascular Events

On November 7, 2026, The New England Journal of Medicine published the results of Lp(a)HORIZON, an international, randomized, placebo-controlled trial. The efficacy analysis included 8,322 patients with established cardiovascular disease and lipoprotein(a) levels ≥70 mg/dL. Participants received monthly subcutaneous pelacarsen 80 mg or placebo. At 12 months, Lp(a) levels were 64.4 nmol/L in the pelacarsen group and 233.4 nmol/L in the placebo group.  Over a median follow-up of 4.7 years, the primary composite endpoint—cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or urgent coronary revascularization—occurred in 12.3% and 12.1% of patients, respectively (hazard ratio, 1.02; 95% CI, 0.90–1.15; P=0.76). No statistically significant benefit was observed in the subgroup with baseline Lp(a) levels ≥90 mg/dL. Thus, the trial did not demonstrate a clinical benefit of pelacarsen over placebo in preventing major adverse cardiovascular events, despite substantial Lp(a) lowering. These findings should not be extrapolated to other therapies targeting lipoprotein(a).


Source: Cho L. et al. NEJM. 2026. DOI: 10.1056/NEJMoa2610159

https://doi.org/10.1016/j.atherosclerosis.2026.121955


Back to the list